Pomerantz LLP Files Class Action Suit Against Tenax Therapeutics and Its Officers for Misleading Investors

Pomerantz Law Firm Takes Legal Action Against Tenax Therapeutics

In a significant legal development, Pomerantz LLP has filed a class action lawsuit against Tenax Therapeutics, Inc. alongside several key officers, in the United States District Court for the Middle District of North Carolina. This legal action, designated under docket number 26-cv-01624, encompasses all individuals and entities that purchased or otherwise obtained securities of Tenax from November 13, 2023, to August 7, 2026, referred to as the "Class Period." The lawsuit seeks to recover damages for violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5.

The lawsuit was prompted by an alarming series of misrepresentations allegedly made by Tenax's officials regarding its primary drug candidate, TNX-103. This medication, evaluated for its effectiveness in treating pulmonary hypertension in heart failure patients, was touted as having potential benefits based on earlier trials. Prior to the Class Period, Tenax proclaimed success in its Phase 2 HELP study, claiming a significant improvement in the six-minute walk distance, a primary endpoint of the subsequent Phase 3 LEVEL study.

However, as the complaint outlines, the truth surrounding TNX-103's efficacy began to unravel on August 10, 2026. On that day, Tenax publicly acknowledged that the drug failed to meet its primary endpoint in the Phase 3 trial, resulting in a dramatic 89.77% drop in the company's stock price, reducing the per-share value to approximately $1.38 from a much higher assessment.

Investors who acquired Tenax securities during the specified Class Period are encouraged to act swiftly. They have until December 28, 2026, to express their intent to the Court to be appointed as Lead Plaintiff in this matter. Interested parties may obtain a copy of the Complaint through Pomerantz's official website or may reach out for discussions about the legal action.

Pomerantz LLP has established itself as a leader in corporate and securities class litigation since its founding by the esteemed Abraham L. Pomerantz. With offices in major cities around the globe including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has a proven track record of recovering billions in damages for its clients. Its mission remains steadfast in advocating for those who have suffered due to corporate misconduct and securities fraud.

The claims laid out in the class action suggest that Tenax, led by its executives, misrepresented the likelihood of TNX-103's success and downplayed the risks, leading investors to believe in unfounded potential that ultimately resulted in significant financial losses. Investors are now faced with the uphill task of clarifying these chaotic circumstances and seeking restitution for their investments.

Anyone affected by this situation should consider joining the class action to bolster their claims and potentially recover losses caused by these alleged deceptions. Interested individuals should prepare to provide their share purchase details and other relevant contact information as part of their inquiry to facilitate the legal processes ahead.

The situation surrounding Tenax serves as a cautionary tale for investors in the pharma sector, reminding them to conduct thorough due diligence and be cautious of overly optimistic claims, especially during crucial clinical trials. As developments unfold in this case, the investment community watches closely, hoping for results that reflect justice and accountability in the world of pharmaceutical investments.